MedPath

A phase 1 study of combination therapy with gemcitabine and candesartan in patients with pancreatic cancer

Phase 1
Conditions
Pancreatic cancer
Registration Number
JPRN-UMIN000002152
Lead Sponsor
niversity of Tokyo, Department of Gastroenterology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
24
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with systolic blood pressure < 100mmHg 2) Patients with an active concomitant infection 3) Patients with digestive ulcer or gastrointestinal bleeding 4) Patients with severe heart or renal disease 5) Patients with an active pulmonary fibrosis or interstitial pneumonia 6) Patients with a previous history of a severe drug hypersensitivity 7) Patients with an active concomitant malignancy 8) Pregnant, lactating female and patients of reproductive potential who did not use effective contraception 9) Patients with hypertension 10) Patients who received ACE or ARB 11) Patients with uncontrollable massive pleural effusion or massive ascites 12) Inappropriate patients for entry on this study in the judgement of the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath